# 1. Financial Performance ## A. Key Figures * **Total Income:** **₹4,508.9 Cr** FY26 (+20%) · **₹1,195.8 Cr** Q4 FY26 (+25%) * **EBITDA (Excl. Noida):** **₹1,134.3 Cr** FY26 (+19%) · **₹314.2 Cr** Q4 FY26 (+27%) * **EBITDA Margin:** **25.7%** FY26 Excl. Noida · **24.2%** FY26 Incl. Noida * **Profit After Tax (PAT):** **₹554.1 Cr** FY26 (+15.1%) · **₹141.7 Cr** Q4 FY26 (+40%) * **Net Cash Balance:** **₹590.6 Cr** as of March 31, 2026 ## B. Revenue & Profitability Trends * **Record Top-Line Momentum:** Robust revenue growth driven by a combination of higher patient volumes, healthy occupancy levels, and improved realizations. * **Margin Expansion Drivers:** Profitability gains supported by operational leverage, with Q4 PAT margins improving to **11.8%**; future gains targeted via material cost optimization and efficiency fixes at the **Gurgaon unit**. * **Network Scaling:** Strong underlying performance across the network, highlighted by a **46.2%** year-on-year increase in specific regional financial metrics. ## C. Balance Sheet & Cash Flow * **Liquidity Strength:** Maintains a significant net cash position to fully fund upcoming growth and expansion initiatives. * **Cash Generation:** Robust operating cash flow generation reflects a consistent **21% 4-year CAGR**, providing a strong foundation for capital deployment. * **Project Accounting Dynamics:** Management highlighted that greenfield hospital cash flows are typically back-ended, creating timing variances between announced CAPEX, CWIP, and final capitalization. --- # 2. Capacity & Infrastructure ## A. Key Figures * **Total Bed Capacity:** **+20.5%** YoY growth · **623** beds added in FY2026 * **Occupancy Rate:** **62%** overall · **64%** excluding Noida · **70%** Patna unit * **Future Pipeline:** **~500** beds (short-term/low capex) · **2,700** beds (3-4 year greenfield) * **New Projects:** **550-bed** Noida facility (operational) · **400+ bed** Guwahati (land acquired) · **400-bed** Varanasi (approved) ## B. Bed Expansion & Utilization * **Aggressive Capacity Scaling:** Significant footprint expansion achieved through the inauguration of the Noida multi-specialty hospital and new commissioning in Ranchi. * **Strategic De-bottlenecking:** Urgent ICU and critical care expansions are underway in Patna and Lucknow to address high utilization and capacity constraints. * **Asset Optimization:** Management is leveraging newly added capacity in Ranchi to facilitate renovations of older infrastructure without disrupting operations. * **Low-Capex Growth:** Plans to add over **200 beds** in the current year with negligible capital outlay by optimizing existing unit footprints. ## C. Project Timelines & Infrastructure Strategy * **Greenfield Roadmap:** Major projects in South Delhi and Mumbai are on a **3-year** construction trajectory, with financial contributions expected to materialize in **FY30**. * **Asset-Light Pivot:** The new Varanasi project utilizes a build-to-suit lease model, limiting company capex to medical equipment and interior fit-outs. * **Regulatory Pipeline:** Expansion projects in Mumbai and Pitampura are currently navigating the regulatory approval phase. ## D. Equipment & Clinical Upgrades * **Procedural Focus:** Shift in strategy toward prioritizing high-value procedural capacity, including **4 new operation theaters** and enhanced cath lab capabilities in Gurgaon. * **Service Diversification:** Infrastructure investments are being paired with clinical expansion, notably the launch of full-fledged cancer services in Indore. * **Surgical Throughput:** Installation of approximately **10 new operation theaters** across the ecosystem to meet local demand for interventional capacity. --- # 3. Clinical & Operational Metrics ## A. Key Figures * **Patient Volumes:** **+16%** Inpatient · **+19%** Outpatient · **+11%** Occupied Bed Days * **Q4 Specific Growth:** **+23%** Inpatient · **+27%** Outpatient · **₹67.9 Cr** International Revenue (+22%) * **ARPOB:** **₹66,550** Group (+6.1%) · **₹56,500** Developing Cluster (+4%) · **₹66,687** Q4 (+5%) * **Occupancy:** **61%** Group · **60%** Developing · **64%** Group excl. Noida ## B. Patient Volumes & Capacity Utilization * **Robust Volume Momentum:** Strong double-digit growth in patient counts and bed days driven by high demand for quality care and expanding regional reach. * **Developing Hospital Velocity:** Significant inpatient volume growth in newer facilities, with Noida expected to accelerate further following **Q1 TPA empanelments**. * **Strategic Positioning:** Management views new capacity (Noida/Dwarka) as additive rather than dilutive to existing facilities, positioning Gurgaon as a premier medical destination. ## C. ARPOB & Clinical Efficiency * **Efficiency-Led Realization:** Group ARPOB growth was significantly bolstered by a reduction in ALOS, continuing a long-term trend toward higher procedural throughput. * **Yield Improvement Levers:** Future ARPOB growth is tied to **tariff adjustments** in Patna (flat for **4.5 years**) and the introduction of Mother and Child services. * **Noida Performance:** Early ARPOB at the Noida facility is tracking between **INR 70,000 to INR 80,000**, though currently skewed by a 100% cash-paying patient mix. ## D. Specialty Mix & High Acuity * **Complexity Shift:** Growth is increasingly driven by high-acuity cases and new-age therapies, including robotic surgeries, TAVIs, and minimally invasive procedures. * **Service Expansion:** Strategic rollout of liver transplants and thoracic surgery in Patna, alongside a second robot in Lucknow, aims to enhance clinical complexity. * **Noida Specialty Ramp-up:** Introduction of pediatrics, obstetrics, and transplant practices expected to diversify the facility's margin profile. ## E. Accreditation & Recognition * **Global Benchmarking:** Medanta Gurugram maintained its status as India’s top-ranked private hospital globally; Lucknow secured **JCI accreditation** in January 2026. * **Ranchi Scaling:** Facility momentum supported by new **NABH accreditation** and CGHS empanelments to drive institutional volume. --- # 4. Segment & Geography Performance ## A. Key Figures * **Mature Hospitals (FY):** **₹2,848.2 Cr** Revenue (+9%) · **₹694.6 Cr** EBITDA (+7%) · **24.4%** Margin * **Mature Hospitals (Q4):** **₹725.7 Cr** Revenue (+11%) · **₹193.5 Cr** EBITDA (+26.7% margin) * **Developing Hospitals (Ex-Noida FY):** **₹1,413 Cr** Revenue (+29%) · **₹447 Cr** EBITDA (+35%) · **31.5%** Margin * **Noida Facility (FY):** **₹90.6 Cr** Revenue · **(₹78.3 Cr)** EBITDA Loss * **International Business:** **₹278 Cr** Revenue (+33%) · **7%** Revenue Contribution ## B. Mature Hospitals * **Operational Efficiency:** Performance was underpinned by robust volume growth and a reduced average length of stay (ALOS) to **3.00 days**, optimizing bed turnover. * **Margin Dynamics:** Full-year margins saw slight compression due to higher personnel costs and the centralization of corporate manpower expenses at the Gurugram unit; however, Q4 margins rebounded strongly. * **Capacity Expansion:** Management is defying industry maturity curves by adding **80 beds** in Indore and investing in new procedural rooms and cath labs in Gurgaon to capture unmet demand. * **Strategic Optimization:** Growth is being driven by a deliberate shift toward a higher-value case mix and improved payer profiles in the flagship Gurgaon facility. ## C. Developing Hospitals * **Noida Ramp-up:** The new flagship is scaling rapidly with **382 beds** operationalized; while currently an EBITDA drag, quarterly losses are narrowing as the facility gains NABH and CGHS credentials. * **High-Complexity Strategy:** Unlike previous launches, Noida opened with a full senior clinical team, enabling immediate high-end procedures in robotics and cardiac care (TAVIs) despite higher initial manpower costs. * **Regional Momentum:** Lucknow and Patna continue to deliver exceptional growth, with occupancy levels reaching **70%** and volumes increasing by nearly a third year-on-year. * **Future Reclassification:** Due to sustained robust performance, management indicated that the Lucknow asset may soon be reclassified as a "mature" hospital. ## D. International Business & Regional Catchments * **Geographic Diversification:** Strong double-digit revenue growth was fueled by expansion into Africa, Southeast Asia, and the CIS, successfully offsetting volatility in Middle Eastern markets. * **Noida Catchment Advantage:** The Noida facility is strategically positioned to aggregate demand from three distinct zones: local Noida, South Delhi, and the underserved Western UP region. --- # 5. Strategic Initiatives & M&A ## A. Key Figures * **Dividend Recommendation:** **₹0.50** per share (25% of face value) * **Clinical Onboarding:** **550+** doctors (incl. 200+ senior clinicians) ## B. Capital Allocation & Inorganic Expansion * **Disciplined M&A Strategy:** Leveraging a robust net cash position to evaluate O&M agreements and M&A transactions, focusing on asset quality and financial viability over greenfield-only projects. * **Regional Cluster Strengthening:** Expanding the Indore footprint with an oncology-focused facility and establishing a major presence in Varanasi to extend reach across North and Northeast India. * **Operational Optimization:** Long-term focus remains on maximizing occupancy, super-specialty mix, and ARPOB through brownfield expansions and sister-market penetration. ## C. Hub-and-Spoke & Network Strategy * **Scalable Growth Model:** Actively executing a hub-and-spoke strategy, using the stabilized **1,000-bed Lucknow facility** as a foundation for regional expansion into Varanasi. * **Future Pipeline:** Evaluating a mix of greenfield and bolt-on opportunities to maintain growth momentum beyond the current NCR stronghold. ## D. Talent Acquisition & Clinical Depth * **Capacity Management:** Aggressive clinical hiring in FY27-FY28 aims to alleviate appointment bottlenecks and manage high patient volumes in Patna and Lucknow. * **Specialty Expansion:** Recruitment is targeted at filling high-value clinical gaps, including the addition of **obstetrics, liver transplants, and chest surgery** in Patna and **advanced pediatrics** in Lucknow. * **Strategic Bench Strength:** Onboarding senior talent ahead of schedule to prepare for future assets, including the **Guwahati facility** slated to open in **3 to 4 years**. * **Advanced Care Focus:** Bolstered clinical capabilities to support high-end procedures such as robotic surgeries and CAR T-cell therapy. --- # 6. Risks & Healthcare Dynamics ## A. Clinical Talent War * **Clinician Retention:** Management reports zero attrition of senior clinicians to date despite upcoming competitive threats, citing a superior clinical value proposition. * **Strategic Recruitment:** Anticipating a broader "war for talent" due to industry-wide shortages, the firm is aggressively hiring from the market to augment existing capacity. ## B. Competitive Entry * **Gurgaon Market Headwinds:** Global Health Limited is bracing for the entry of **two new competitor hospitals** in the Gurgaon cluster, slated for launch around **September-October**. * **Noida Scaling Confidence:** Management asserts no structural risk to demand or ramp-up speed in Noida, claiming sufficient clinical "firepower" to compete with regional incumbents. ## C. Regulatory & Payer Mix * **Insurance Onboarding:** The Noida facility has transitioned from cash-only to accepting TPA/Insurance schemes, with nearly all major empanelments finalized post-March 31st. * **Government Payer Pipeline:** Future volume growth is expected to be supported by the onboarding of **CGHS and railway** schemes, contingent upon infrastructure availability. --- # 7. Guidance & Outlook ## A. Key Figures * **Capex Pipeline:** **₹4,500 Cr** total 5-year projection · **₹800–900 Cr** FY27 · **₹600–700 Cr** FY28 * **Target Margins:** **24%–25%** for matured units * **Growth Targets:** **20%–30%** revenue growth for Ranchi unit * **Noida Break-even Threshold:** **40%–45%** occupancy (current: **30%**) ## B. Break-even Targets * **Noida Path to Profitability:** Management expects the Noida unit to reach break-even in H2 of the current fiscal, following operational ramp-up patterns established at Lucknow and Patna. ## C. Capex Projections * **Expansion Funding:** Long-term capital expenditure is slated to be financed through a combination of internal accruals and project-specific debt. ## D. Growth Trajectory * **Mature Unit Stability:** Margins at established facilities are expected to remain steady, with potential tailwinds from **tariff revisions** and **CGHS benefits**. * **Ranchi Scaling:** Significant revenue acceleration anticipated in Ranchi as it transitions to a single-campus model with the addition of high-value specialties like **oncology**. * **Market Outlook:** Sustained momentum expected across all service lines for the full year, supported by evolving payer mixes and a robust domestic healthcare opportunity.